Universal Med Finl & (2666) Fair Value & Analysis
Financial Services · HK · Market cap HK$9.0B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 3 days ago
Fair value updated Aug 13, 2026, revised from HK$6.65 to HK$6.66 (+0.1%) since Aug 6, 2026. Share price −2.6% over the past month.
A solid business, screening 44% undervalued on our models.
What matters now
- Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (HK$4.35 to HK$8.32) leaves room in how you read the outcome.
- For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$2.43 – HK$6.16 · fair‑value band HK$4.35 – HK$8.32 · the HK$4.64 price screens below the HK$6.66 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Universal Med Finl & (2666) currently trades at HK$4.64, while our model-based Fair Value estimate is HK$6.66, implying the stock looks roughly 43.6% undervalued today. The Quality Score stands at 61/100 (solid quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Universal Med Finl & generated revenue of HK$14.5B at a net margin of 15.2%. Revenue grew 2.3% year over year. It earns a return on equity of 9.7%. Net debt stands at HK$47.4B. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$4.35 (bear case) to HK$8.32 (bull case); at HK$4.64, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 25% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Financial Services peers we cover trades at -45% fair-value upside, at 44%, 2666 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (HK$31.18) versus Dividend Discount (HK$4.62). Highest evidence: Growth DCF (80).
Notify me when 2666 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Genertec Universal Medical Group Company Limited, together with its subsidiaries, provides financing, advisory, and medical services in the Mainland China. It operates through two segments, Finance Business and Healthcare Business.
Full company description
Genertec Universal Medical Group Company Limited, together with its subsidiaries, provides financing, advisory, and medical services in the Mainland China. It operates through two segments, Finance Business and Healthcare Business. The Finance Business segment offers direct finance leasing; sale and leaseback; factoring; operating leases; and advisory services. Its Healthcare Business segment includes medical and healthcare services; hospital operations; import, export, and trading of medical-related goods; equipment life cycle management; medical digitalization services; and intelligent medical health and elder care. The company also provides medical and professional technology, financing, hospital management, medical consulting, sale of medical related goods, medical, software development, and elderly care services. It serves patients, hospitals, medical equipment suppliers, and other public institutions. The company was formerly known as Universal Medical Financial & Technical Advisory Services Company Limited and changed its name to Genertec Universal Medical Group Company Limited in July 2018. The company was founded in 1984 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Universal Med Finl & reported revenue of HK$14.5B in FY2025 versus HK$9.6B in FY2021, a compound +11.0%/yr. Reported net income was HK$2.2B in FY2025, compounding +3.2%/yr from FY2021.
of which total revenue +23.1 pp · buybacks/dilution −5.3 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 2666: get an alert when its fair value changes →
Peer Group
Credit Services · 333 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Credit Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Credit Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Visa Inc V | $359.42 | $198.27 | -45% |
| Mastercard Incorporated MA | $561.44 | $221.87 | -60% |
| Bajaj Finance Limited BAJFINANCE | ₹1,094 | ₹397.61 | -64% |
| Shriram Finance Limited SHRIRAMFIN | ₹1,117 | ₹553.83 | -50% |
| Cholamandalam Investment and Finance Company CHOLAFIN | ₹1,918 | ₹796.52 | -58% |
| Tata Capital Limited TATACAP | ₹367.05 | ₹149.40 | -59% |
| Power Finance Corporation PFC | ₹376.50 | ₹615.85 | +64% |
| Muthoot Finance Limited MUTHOOTFIN | ₹2,876 | ₹3,429 | +19% |
| Indian Railway Finance Corporation IRFC | ₹88.35 | ₹69.72 | -21% |
| REC Limited RECLTD | ₹346.00 | ₹692.00 | +100% |
Compare Universal Med Finl & with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is Universal Med Finl & (2666) overvalued or undervalued?
What is the fair value of 2666?
What is the quality score of 2666?
What is the revenue of Universal Med Finl & (2666)?
What is the net profit margin of 2666?
Does Universal Med Finl & pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Universal Med Finl & and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.